Matthias Cavassini

Has grant

University Name

Switzerland

Research Interests

Explore related searches

Professors in Switzerland

Contact this professor

ORCID

Google Scholar

Academic Page

Recent Grants

Grant: Close

Model-Based Simulation and Clinical Validation of Drug-Drug Interactions in the Swiss HIV Cohort Study

Open Date: 2016-09-01

Close Date: 2019-08-31

Grant: Close

Longitudinal Neurocognitive Assessment in the Metabolic and Aging Cohort of the Swiss HIV Cohort Study: the NAMACO study

Open Date: 2016-01-01

Close Date: 2018-12-31

Grant: Close

Swiss HIV Cohort Study (SHCS)

Open Date: 2014-01-01

Close Date: 2017-12-31

Grant: Close

Prognosis of HIV-positive patients treated with antiretroviral therapy: comparative analyses and treatment strategies

Open Date: 2012-02-01

Close Date: 2015-01-31

Grant: Close

Swiss HIV Cohort Study

Open Date: 2006-04-01

Close Date: 2010-12-31

Articles (29)

HIV-1 Low-Level Viremia Predicts Viral Failure in Participants on Antiretroviral Therapy in the Swiss HIV Cohort Study.

Article Link

Year:

2025

Polygenic Risk Scores for Type 2 Diabetes in the Swiss HIV Cohort Study

Article Link

Year:

2025

Population pharmacokinetics of bictegravir in real-world people with HIV

Article Link

Year:

2025

Is Nonsustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Really Independent of Drug Levels?

Article Link

Year:

2025

Trends in Costs for HIV Care During a Hepatitis C Virus Early Treatment and Elimination Program: A Data Linkage Study of Claims and Swiss HIV Cohort Study Data

Article Link

Year:

2025

Risk of Cancer in People With Human Immunodeficiency Virus Experiencing Varying Degrees of Immune Recovery With Sustained Virological Suppression on Antiretroviral Treatment for More Than 2 Years: An International, Multicenter, Observational Cohort

Article Link

Year:

2025

Genetic Diversity From Proviral DNA as a Proxy for Time Since HIV-1 Infection

Article Link

Year:

2024

Guidance for the Interpretation of Long-Acting Cabotegravir and Rilpivirine Concentrations Based on Real-World Therapeutic Drug Monitoring Data and Documented Failures

Article Link

Year:

2024

Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland

Article Link

Year:

2024

Time Trends in Causes of Death in People With HIV: Insights From the Swiss HIV Cohort Study

Article Link

Year:

2024

Self-reported neurocognitive complaints in the Swiss HIV Cohort Study: a viral genome-wide association study

Article Link

Year:

2024

Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long‐Acting Intramuscular Injection in Real‐World People with HIV

Article Link

Year:

2024

Deciphering Factors Linked With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Susceptibility in the Swiss HIV Cohort Study

Article Link

Year:

2024

Randomised, double-blind, controlled phase 1 trial of the candidate tuberculosis vaccine ChAdOx1-85A delivered by aerosol versus intramuscular route

Article Link

Year:

2024

Impact of hormonal therapy on HIV‐1 immune markers in cis women and gender minorities

Article Link

Year:

2024

Long‐term trends in hepatitis C prevalence, treatment uptake and liver‐related events in the Swiss HIV Cohort Study

Article Link

Year:

2024

Advances in assessment and cognitive neurorehabilitation of HIV-related neurocognitive impairment

Article Link

Year:

2024

Efficacy and Safety of Dolutegravir Plus Emtricitabine vs Combined Antiretroviral Therapy for the Maintenance of HIV Suppression: Results Through Week 144 of the SIMPL’HIV Trial

Article Link

Year:

2024

One for all, all for one: neuro‐HIV multidisciplinary platform for the assessment and management of neurocognitive complaints in people living with HIV

Article Link

Year:

2023

Prevalence of HIV-1 drug resistance mutations in proviral DNA in the Swiss HIV Cohort Study, a retrospective study from 1995 to 2018

Article Link

Year:

2023

Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration

Article Link

Year:

2023

Quantifying and Predicting Ongoing Human Immunodeficiency Virus Type 1 Transmission Dynamics in Switzerland Using a Distance-Based Clustering Approach

Article Link

Year:

2023

Epigenetic ageing accelerates before antiretroviral therapy and decelerates after viral suppression in people with HIV in Switzerland: a longitudinal study over 17 years.

Article Link

Year:

2023

Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor containing regimen.

Article Link

Year:

2023

[2023 update on alveolar echinococcosis].

Article Link

Year:

2023

[Innovative responses to HIV-related issues in a university hospital in Switzerland].

Article Link

Year:

2023

[Multidisciplinary assessment and management of neurocognitive complaints in people living with HIV].

Article Link

Year:

2023

Low Risk of Failing Direct-Acting Antivirals in People With Human Immunodeficiency Virus/Hepatitis C Virus From Sub-Saharan Africa or Southeastern Asia: A European Cross-Sectional Study

Article Link

Year:

2022

Risk Factors and Incidence of Sexually Transmitted Infections in the Swiss HIV Cohort Study

Article Link

Year:

2022

Collaborators (26)

Michael Huber

Head Diagnostics and Development

University of Zurich

SWITZERLAND

Thierry Buclin

SWITZERLAND

Roger D Kouyos

University Hospital of Zurich

SWITZERLAND

Katharina Kusejko

University of Zurich

SWITZERLAND

Alexandre Berney

Associate Professor

Lausanne University Hospital

SWITZERLAND

Maxime HENTZIEN

Full Professor in Infectious Diseases

Université de Reims Champagne-Ardenne

FRANCE

Enos Bernasconi

Chief

SWITZERLAND

Irene Abela

University of Zurich

SWITZERLAND

Hans H. Hirsch

SWITZERLAND

Caroline Sabin

University College London

UNITED KINGDOM

Aline Munting

Chief resident

Centre Hospitalier Universitaire Vaudois

SWITZERLAND

Anthony Hauser

SWITZERLAND

Jacques Fellay

Associate Professor

University of Lausanne

SWITZERLAND

Cristina Granziera

SWITZERLAND

Julia Notter

University Hospital Basel

SWITZERLAND

Amanda Mocroft

University College London

UNITED KINGDOM

Carlotta Riebensahm

University Hospital of Bern

SWITZERLAND

Alexandra Trkola

University of Zurich

SWITZERLAND

Monia Guidi

SWITZERLAND

Catia Marzolini

University Hospital Basel

SWITZERLAND

Niklaus D Labhardt

University Hospital Basel

SWITZERLAND

A. Ramette

University of Bern

SWITZERLAND

Karin J. Metzner

University of Zurich

SWITZERLAND

Huldrych Günthard

Professor, MD

University Hospital of Zurich

SWITZERLAND

Laurent Decosterd

Head of the Laboratory of Clinical Pharmacology / Associated Professor

Centre Hospitalier Universitaire Vaudois

SWITZERLAND

Katharine Darling

Lausanne University Hospital

SWITZERLAND

Matthias Cavassini

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (29)

HIV-1 Low-Level Viremia Predicts Viral Failure in Participants on Antiretroviral Therapy in the Swiss HIV Cohort Study.

Polygenic Risk Scores for Type 2 Diabetes in the Swiss HIV Cohort Study

Population pharmacokinetics of bictegravir in real-world people with HIV

Is Nonsustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Really Independent of Drug Levels?

Trends in Costs for HIV Care During a Hepatitis C Virus Early Treatment and Elimination Program: A Data Linkage Study of Claims and Swiss HIV Cohort Study Data

Risk of Cancer in People With Human Immunodeficiency Virus Experiencing Varying Degrees of Immune Recovery With Sustained Virological Suppression on Antiretroviral Treatment for More Than 2 Years: An International, Multicenter, Observational Cohort

Genetic Diversity From Proviral DNA as a Proxy for Time Since HIV-1 Infection

Guidance for the Interpretation of Long-Acting Cabotegravir and Rilpivirine Concentrations Based on Real-World Therapeutic Drug Monitoring Data and Documented Failures

Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland

Time Trends in Causes of Death in People With HIV: Insights From the Swiss HIV Cohort Study

Self-reported neurocognitive complaints in the Swiss HIV Cohort Study: a viral genome-wide association study

Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long‐Acting Intramuscular Injection in Real‐World People with HIV

Deciphering Factors Linked With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Susceptibility in the Swiss HIV Cohort Study

Randomised, double-blind, controlled phase 1 trial of the candidate tuberculosis vaccine ChAdOx1-85A delivered by aerosol versus intramuscular route

Impact of hormonal therapy on HIV‐1 immune markers in cis women and gender minorities

Long‐term trends in hepatitis C prevalence, treatment uptake and liver‐related events in the Swiss HIV Cohort Study

Advances in assessment and cognitive neurorehabilitation of HIV-related neurocognitive impairment

Efficacy and Safety of Dolutegravir Plus Emtricitabine vs Combined Antiretroviral Therapy for the Maintenance of HIV Suppression: Results Through Week 144 of the SIMPL’HIV Trial

One for all, all for one: neuro‐HIV multidisciplinary platform for the assessment and management of neurocognitive complaints in people living with HIV

Prevalence of HIV-1 drug resistance mutations in proviral DNA in the Swiss HIV Cohort Study, a retrospective study from 1995 to 2018

Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration

Quantifying and Predicting Ongoing Human Immunodeficiency Virus Type 1 Transmission Dynamics in Switzerland Using a Distance-Based Clustering Approach

Epigenetic ageing accelerates before antiretroviral therapy and decelerates after viral suppression in people with HIV in Switzerland: a longitudinal study over 17 years.

Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor containing regimen.

[2023 update on alveolar echinococcosis].

[Innovative responses to HIV-related issues in a university hospital in Switzerland].

[Multidisciplinary assessment and management of neurocognitive complaints in people living with HIV].

Low Risk of Failing Direct-Acting Antivirals in People With Human Immunodeficiency Virus/Hepatitis C Virus From Sub-Saharan Africa or Southeastern Asia: A European Cross-Sectional Study

Risk Factors and Incidence of Sexually Transmitted Infections in the Swiss HIV Cohort Study

Collaborators (26)

Michael Huber

Thierry Buclin

Roger D Kouyos

Katharina Kusejko

Alexandre Berney

Maxime HENTZIEN

Enos Bernasconi

Irene Abela

Hans H. Hirsch

Caroline Sabin

Aline Munting

Anthony Hauser

Jacques Fellay

Cristina Granziera

Julia Notter

Amanda Mocroft

Carlotta Riebensahm

Alexandra Trkola

Monia Guidi

Catia Marzolini

Niklaus D Labhardt

A. Ramette

Karin J. Metzner

Huldrych Günthard

Laurent Decosterd

Katharine Darling

How do I reach out?

Meet Kite AI